Skip to main content
BIOX
NASDAQ Trade & Services

Bioceres Q1 Revenue Falls 22%, Net Loss Widens to $10.8M as Liquidity Tightens

Tom Rudovsky · Reported by BusinessWire
More coverage: Industrial
Sentiment info
Negative
Importance info
7
Price
$0.233
Mkt Cap
$14.85M
52W Low
$0.19
52W High
$2.03
52W Position info
22% above low
Off High info
89% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

BIOX sits 22% above its 52-week low of $0.19 on light trading volume (0.3× avg).

Summary

Revenue fell 22% to $53.8 million and gross profit dropped 39% to $18.8 million, with gross margin collapsing to 35.0% from 44.5%. The net loss from continuing operations widened to $10.8 million from $4.7 million, and Adjusted EBITDA fell to $5.3 million from $13.9 million a year ago. Management blamed delayed soybean seed-treatment sales, a tougher competitive environment in Argentina, and limited financial flexibility that hurt categories needing longer-term financing. The balance sheet is the real problem: cash is down to $8.7 million against $221.7 million of total financial debt, and the full $112 million of secured notes stays classified as short-term after the noteholders' acceleration notices. This lands after the 20-F disclosed substantial doubt about going concern and the Nasdaq bid-price extension to March 15, 2027, so the weak quarter compounds an already fragile capital structure. The one offset is sequential Adjusted EBITDA improvement for a second straight quarter, from negative $0.6 million in 3Q26 to $5.3 million now.

At the time of this announcement, BIOX was trading at $0.23 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $14.8M. The 52-week trading range was $0.19 to $2.03. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

BIOX - Latest Insights

BIOX
Oct 30, 2026, 5:04 PM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $0.208
Real-time Price: $0.2327 info
Change: +$0.0247 (+12%) info
Market Cap: $14.85M info
BIOX
Sep 21, 2026, 6:09 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.346
Real-time Price: $0.2327 info
Change: -$0.1133 (-33%) info
Market Cap: $14.85M info
BIOX
Sep 15, 2026, 7:04 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.392
Real-time Price: $0.2327 info
Change: -$0.1593 (-41%) info
Market Cap: $14.85M info
BIOX
Sep 14, 2026, 6:43 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $0.4342
Real-time Price: $0.2327 info
Change: -$0.2015 (-46%) info
Market Cap: $14.85M info
BIOX
Jul 07, 2026, 7:08 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.3294
Real-time Price: $0.2327 info
Change: -$0.0967 (-29%) info
Market Cap: $14.85M info